Since 18 of December 2019 conferences.iaea.org uses Nucleus credentials. Visit our help pages for information on how to Register and Sign-in using Nucleus.

Carbon Ion Radiotherapy for Prostate Cancer; a nationwide survey of the Japan Carbon-ion Radiation Oncology Study Group (J-CROS 1501)

Jun 22, 2017, 9:25 AM
10m
Oral Presentation Clinical Radiation Oncology Session 16a - Prostate - H&N

Speaker

Hidemasa Kawamura (Gunma University)

Description

**Introduction of the study;** Multi-institutional analysis of the patients with prostate cancer who have received carbon ion radiotherapy (CIRT) as the prospective study in each institute of the Japan Carbon-ion Radiation Oncology Study Group (J-CROS) was carried out.
**Methodology;** Data of patients enrolled in prospective clinical trials performed at National institute of radiological science, Gunma university heavy ion medical center and Ion beam therapy center, SAGA-HIMAT foundation were retrospectively analyzed. CIRT dose and fractionations were 66-63Gy(RBE)in 20 fractions, 57.6Gy(RBE) in 16 fractions or 51.6Gy(RBE) in 12fractions.All patient risks were reclassified according to the D'Amico risk classification. A short-term (6 months) androgen deprivation therapy (ADT) and a long-term (≥24 months) ADT were combined with CIRT for the intermediate-risk group and the high-risk group, respectively. ADT was not combined in low-risk group. The biochemical failure was defined as a rise of >2.0 ng/mL above PSA nadir (Phoenix definition).
**Results;** Between December 2003 and December 2014, the total number of enrolled patients from all three institutions was 2157. The number of patients in low-risk, intermediate-risk, and high-risk groups were 263, 679, and 1215, respectively. A total of 1754 patients (82%) underwent ADT. The median follow-up periods of surviving patients was 29 months. The five-year biochemical relapse-free survivals (bRFS) in low-risk, intermediate-risk, and high-risk patients were 92%, 89%, and 92%, respectively. The ten-year bRFS in low-risk, intermediate-risk, and high-risk patients were 77%, 70%, and 79%, respectively. The five-year local control rates (LCR) and cause-specific survivals (CSS) in low-risk, intermediate-risk, and high-risk patients were 98%, 96%, and 99% for LCR, respectively, and 100%, 100%, and 99% for CSS, respectively. The incidence of grade (G) 2 and G3 late toxicities were 4.5% and 0% for the bladder, and 0.5% and 0% for the rectum, respectively.
**Conclusion;** Analysis of the first multi-institutional data on CIRT for prostate cancer suggested that the treatment outcomes of CIRT were favorable, especially in high-risk group patients.
Country JAPAN
Institution Gunma University Heavy Ion Medical Center

Primary author

Hidemasa Kawamura (Gunma University)

Co-authors

Hiroshi TSUJI (National Institute of Radiological Sciences) Nobuteru Kubo (Gunma University) Shingo TOYAMA (SAGA-HIMAT Foundation) Tadashi KAMADA (National Institute of Radiological Sciences) Takashi Nakano (Gunma University) Takuma NOMIYA (Kanagawa Cancer Center) Tatsuji Mizukami (Gunma University) Tatsuya OHNO (Gunma University) Yoshiyuki SHIOYAMA (SAGA-HIMAT Foundation)

Presentation materials